UK Markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.25-0.37 (-6.58%)
As of 01:23PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.62
Bid5.26 x 900
Ask5.27 x 1300
Day's range5.20 - 5.68
52-week range2.87 - 17.85
Avg. volume8,335,420
Market cap368.063M
Beta (5Y monthly)1.38
PE ratio (TTM)N/A
EPS (TTM)-9.95
Earnings date21 Feb 2022 - 25 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.33
  • Motley Fool

    Is This Growth Stock Undervalued?

    Biotech company Bluebird Bio (NASDAQ: BLUE) is currently riding high. Despite these accomplishments, Bluebird is still a tiny company with a market cap of just $475 million. Of note, Skysona had previously earned marketing authorization in Europe, but Bluebird exited the European market last year for reasons that may also prove to be a challenge in the U.S. (more on that in a bit).

  • Motley Fool

    Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?

    This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.

  • Zacks

    Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

    Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.